Evidence map›Paper›PMID 18811803›Full record

ArticlePacing and clinical electrophysiology : PACE2008

Ventricular arrhythmias after left ventricular assist device implantation.

Marwan Refaat, Elie Chemaly, Djamel Lebeche, Judith K Gwathmey, Roger J Hajjar

Open access · greenAbstract read
In one paragraph

Article in Pacing and clinical electrophysiology : PACE, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Clinical implications of left ventricular assist device implantation in patients with an implantable cardioverter-defibrillator.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2014
    Trial
  3. Atrial fibrillation in continuous flow-left ventricular assist device (CF-LVAD) patients: impact on pathophysiology.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025
    Review
  4. Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device's patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Article
  5. Design and characteristics of the prophylactic intra-operative ventricular arrhythmia ablation in high-risk LVAD candidates (PIVATAL) trial.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Ventricular arrhythmias in patients with biventricular assist devices.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2020
    Article
  13. Article
  14. Benefits of Neurohormonal Therapy in Patients With Continuous-Flow Left Ventricular Assist Devices.ASAIO journal (American Society for Artificial Internal Organs : 1992) · 2020
    Article
  15. Article
  16. Heart failure as a substrate and trigger for ventricular tachycardia.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2019
    Review
  17. ICD shocks in LVAD patients are not associated with increased subsequent mortality risk.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2019
    Article
  18. Ventricular Arrhythmias in Patients With Left Ventricular Assist Device (LVAD).Current treatment options in cardiovascular medicine · 2019
    Review
  19. Hurdles to Cardioprotection in the Critically Ill.International journal of molecular sciences · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Marwan RefaatDivisions of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA. rifaatmarwan@hotmail.com
Elie Chemaly
Djamel Lebeche
Judith K Gwathmey
Roger J Hajjar
Icahn School of Medicine at Mount Sinai · USHarvard University · USUniversity of Pittsburgh Medical Center · US

Funding

Targeting Calcium Cycling in Pre-Clinical Model CardiacR01HL083156 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HAJJAR, ROGER J. · 2006 to 2010
$1.7M
Gene Therapy with Cardiotropic Vectors for the Treatment of Heart FailureR01HL088434 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAJJAR, ROGER J. · 2010 to 2013
$1.7M
NHLBI NIH HHS R01 HL083156NHLBI NIH HHS R01 HL088434
6 · The paper itself

Abstract

backgroundLeft ventricular assist devices (LVADs) have been used as a bridge to cardiac transplantation and as destination therapy in patients with advanced heart failure. The period after LVAD support is associated with ventricular arrhythmias (VAs) despite ventricular unloading and such VAs can have a detrimental effect on survival. Despite the increasing use of LVAD, little is known regarding post-LVAD VAs at the molecular level and in vivo.

methodsForty-two patients who received LVAD over a 24-month period were evaluated and grouped on the basis of the presence or absence of VAs during LVAD support. We completed a comparative microarray analyses between six patients who developed ventricular tachycardia (VT) or ventricular fibrillation (VF) after LVAD support and six patients who did not develop VAs after LVAD.

resultsVAs occurred in 15 patients (35.7%) during LVAD support at a median post-LVAD day of 25.2. VAs were strongly associated with nonusage of a beta-blocker post-LVAD (odds ratio of 7.04, P-value = 0.001). Analysis of a subset of patients who had VT or VF after LVAD placement showed a decrease in the expression of connexin 43 (0.48 +/- 0.07), Na+/K+-ATPase (0.60 +/- 0.05), and voltage-gated K+ channel Kv4.3 (0.42 +/- 0.04), and an increase in Na+/Ca2+ exchanger (2.2 +/- 0.4) and the structural genes: Titin (2.1 +/- 0.2), laminin (1.7 +/- 0.4), calsequestrin (1.8 +/- 0.5), skeletal muscle isoform of troponin T (5.1 +/- 0.9), and skeletal muscle isoform of troponin I (3.9 +/- 0.7).

conclusionAfter LVAD, the increased risk of VAs is strongly associated with nonusage of beta-blocker postoperatively.

Indexed as

Adrenergic beta-AntagonistsCohort StudiesHeart-Assist DevicesHumansLongitudinal StudiesRetrospective StudiesTachycardia, VentricularTreatment OutcomeAdrenergic beta-Antagonists

Identifiers

PMID18811803
PMCPMC2752870
OpenAlexW2137002261

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.